文献速递消化系统肿瘤

新型治疗前基因表达风险评分指导胃癌治疗

A novel pretherapeutic gene expression-based risk score for treatment guidance in gastric cancer.
PubMed 文献 · Ann Oncol · 2018-01-01

该研究基于626例胃及胃食管交界癌患者,建立并验证了包含CCL5、CTNNB1、EXOSC3、LZTR1表达及cT、肿瘤部位、组织病理类型的预后风险评分,在训练集和验证集中均显示高低风险组总生存有显著差异,且在不同治疗亚组中一致。

要点

  • 风险评分包含4个基因表达及cT、肿瘤部位、组织学类型。
  • 验证集HR 0.32(95%CI 0.21-0.51,P<0.001)区分高低风险。
  • 原发切除及围手术期治疗亚组中风险评分均与OS显著相关。

核心结论

  • 该风险评分可能有助于改善围手术期化疗背景下胃癌患者的管理。

研究设计与样本

  • 分析两个学术中心626例胃及胃食管交界癌,分训练集269例和验证集357例。
  • 通过定量PCR检测切除肿瘤中11个目标基因表达,建立并验证预测总生存的风险评分。
  • 通过分析10例患者50个肿瘤区域评估瘤内异质性。

主要发现

  • 风险评分包含CCL5、CTNNB1、EXOSC3和LZTR1表达及cT、肿瘤定位和组织病理类型,高低风险组OS差异显著(HR 0.30;95%CI 0.17-0.52)。
  • 独立验证集中风险评分成功验证(HR 0.32;95%CI 0.21-0.51;P<0.001)。
  • 原发切除亚组HR 0.30(95%CI 0.17-0.54;P<0.001),术前/围手术期治疗亚组HR 0.37(95%CI 0.17-0.81;P=0.009)。
  • 原发切除的肠型癌HR 0.45(95%CI 0.23-0.90;P=0.020),非肠型癌HR 0.1(95%CI 0.02-0.42;P<0.001)。
  • 瘤内异质性分析显示,假设分析3个活检标本的分类可靠性为95%。

临床怎么用

  • 该风险评分可能辅助围手术期化疗背景下胃癌患者的治疗决策。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Perioperative chemotherapy is an established treatment of advanced gastric cancer patients. Treatment selection is based on clinical staging (cT). We aimed to establish and validate a prognostic score including clinical and molecular factors, to optimize treatment decisions for these patients. PATIENTS AND METHODS: We analyzed 626 carcinomas of the stomach and of the gastro-esophageal junction from two academic centers including primarily resected and pre-/perioperatively treated patients. Patients were divided into a training (N = 269) and validation (N = 357) set. Expression of 11 target genes was measured by quantitative PCR in resected tumors. A risk score to predict overall survival (OS) was generated and validated. Intra-tumoral heterogeneity was assessed by analyzing 50 tumor areas from 10 patients. RESULTS: A risk score including the expression of CCL5, CTNNB1, EXOSC3 and LZTR1 and the clinical parameters cT, tumor localization and histopathologic type suggested two groups with a significant difference in OS [hazard ratio (HR) 0.30; 95% confidence interval (CI) 0.17-0.52]. The risk score was successfully validated in an independent cohort (HR 0.32; 95% CI 0.21-0.51; P < 0.001) as well as in subgroups of primarily resected (HR 0.30; 95% CI 0.17-0.54; P < 0.001) and pre-/perioperatively treated patients (HR 0.37; 95% CI 0.17-0.81; P = 0.009). A significant difference in OS of high- and low-risk patients was also found in primarily resected patients with intestinal (HR 0.45; 95% CI 0.23-0.90; P = 0.020) and nonintestinal-type carcinomas (HR 0.1; 95% CI 0.02-0.42; P < 0.001). Intra-tumor heterogeneity analysis indicated a classification reliability of 95% for a supposed analysis of three biopsies. CONCLUSION: The identified risk score could substantially contribute to an improved management of gastric cancer patients in the context of perioperative chemotherapy.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Bauer L, Hapfelmeier A, Blank S, et al. A novel pretherapeutic gene expression-based risk score for treatment guidance in gastric cancer. Ann Oncol. 2018. PMID: 29069277. doi:10.1093/annonc/mdx685

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。